Disjointed: Cell Differences May Explain Why Rheumatoid Arthritis Varies By Location

Findings point to new approaches in targeted therapies so that what works for arthritic hands may not be the same for ailing hips —

Researchers at the University of California San Diego School of Medicine, with colleagues in Pennsylvania and China, report that not only are there distinct differences in key cellular processes and molecular signatures between rheumatoid arthritis (RA) and osteoarthritis (OA) but, more surprisingly, there are joint-specific differences in RA. The findings help explain, in part, why drugs treating RA vary in effect – why, for example, a treatment that might work in arthritic knees isn’t effective in an arthritic hip – and provide a potential new template for precisely targeting treatment for each and every ailing joint. … Read the Full Story from the UC San Diego Newsroom


Dr. Gary Firestein

Dr. Gary S. Firestein

Gary S. Firestein, MD, Professor of Medicine in the Division of Rheumatology, Allergy & Immunology, is co-corresponding author of the study report with Wei Wang, PhD, professor in the departments of Chemistry and Biochemistry and Cellular and Molecular Medicine at UC San Diego.

Dr. Firestein is Director of the Clinical and Translational Research Institute (CTRI) and Dean and Associate Vice Chancellor of Translational Medicine for UC San Diego.

A Department of Medicine faculty coauthor of the report is David L. Boyle, Professor of Medicine in the Division of Rheumatology, Allergy & Immunology and Co-Director, Translational Research Technology, CTRI.

Read the study report (UC San Diego Only)

Personalized Medicine Leads to Better Outcomes for Patients with Cancer

In a meta-analysis of hundreds of clinical trials involving thousands of patients, researchers at University of California San Diego School of Medicine report that therapeutic approaches using precision medicine, which emphasizes the use of individual genetics to refine cancer treatment, showed improved response and longer periods of disease remission, even in phase I trials.

The findings are published in the June 6, 2016 issue of JAMA Oncology. … Read the Full Story from the UC San Diego Newsroom


Dr. Razelle Kurzrock

Dr. Razelle Kurzrock

The senior author of the report in JAMA Oncology is Razelle Kurzrock, MD, Director of the Center for Personalized Cancer Therapy and Clinical Trials Office at Moores Cancer Center.

Dr. Kurzrock is Chief of the Division of Hematology-Oncology in the Department of Medicine.

UC San Diego, UC San Francisco Launch New Cancer Cell Mapping Initiative

Researchers from the University of California, San Diego School of Medicine and University of California, San Francisco, with support from a diverse team of collaborators, have launched an ambitious new project – dubbed the Cancer Cell Map Initiative or CCMI – to determine how all of the components of a cancer cell interact.

“We’re going to draw the complete wiring diagram of a cancer cell,” said Nevan Krogan, PhD, director of the UC San Francisco division of QB3, a life science research institute and accelerator, an investigator at Gladstone Institutes and co-director of CCMI with Trey Ideker, PhD, chief of medical genetics in the UC San Diego Department of Medicine and founder of the UC San Diego Center for Computational Biology & Bioinformatics. … Read the full story from the UC San Diego Newsroom

 


Trey Ideker, PhD

Trey Ideker, PhD

Trey Ideker, PhD, is professor of bioengineering and professor of medicine in the Division of Medical Genetics. He was recently named a fellow of the American Association for the Advancement of Science (AAAS).

Dr. Ideker’s Laboratory Website